Innovative Collaboration between Salipro Biotech and Daewoong Pharmaceutical
- The collaboration combines Salipro Biotech's unique expertise and its Salipro platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs.
Swedish biotechnology firm Salipro Biotech AB has recently announced an exciting research collaboration with Daewoong Pharmaceutical Co., Ltd. This agreement allows Daewoong to leverage Salipro Biotech's specialized expertise and proprietary Salipro technology, which focuses on stabilizing challenging membrane proteins, including G protein-coupled receptors (GPCRs), ion channels, and transporters. This collaboration primarily aims to target a specific membrane protein, facilitating Daewoong's development of novel small molecule drugs.
Enhancing Drug Discovery
Within the framework of this agreement, Daewoong Pharmaceutical can tap into Salipro's advanced platform, significantly enhancing its drug discovery efforts. These efforts are geared towards creating innovative small therapeutics aimed at addressing challenging membrane protein drug targets that have previously posed significant hurdles in the field.
CEO of Salipro Biotech, Jens Frauenfeld, expressed enthusiasm about this partnership: "We are excited to join forces with Daewoong Pharmaceutical and contribute our proprietary Salipro platform to accelerate the development of novel therapeutic drugs for Daewoong's pipeline. This partnership is particularly significant as it marks our first collaboration with a partner in a vibrant pharmaceutical market, underscoring the global application and versatility of our expertise to make the undruggable druggable."
Building on Industry Expertise
Seongsoo Park, CEO at Daewoong Pharmaceutical, highlighted the value of this collaboration: "Collaborating with Salipro Biotech and accessing their Salipro platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will streamline our research towards novel small molecule therapeutics, and we eagerly anticipate the outcomes of our joint efforts."
About Salipro Biotech AB
Salipro Biotech AB is a privately held company pioneering in the field of biotechnology, focused on unlocking challenging drug targets to develop next-generation therapeutics. Headquartered in Stockholm, Sweden, Salipro has a comprehensive intellectual property portfolio covering the Salipro platform technology, which stabilizes membrane proteins, facilitating their use in drug discovery initiatives.
Understanding Membrane Proteins
Most drug targets are recognized as membrane proteins, which are inherent challenges due to their instability. Salipro's innovative technology stabilizes these proteins in their native form, allowing them to be effectively incorporated into drug discovery programs that support therapeutic antibodies, small molecule drugs, and structure-based drug design. Salipro Biotech has already established numerous successful research collaborations with top-tier pharmaceutical and biotech firms, emphasizing their commitment to accelerating the discovery of groundbreaking drugs.
About Daewoong Pharmaceutical
Founded in 1945, Daewoong Pharmaceutical is a global player in the pharmaceutical industry, dedicated to developing, manufacturing, and marketing a comprehensive array of pharmaceutical products. With a mission centered on enhancing the quality of life for its consumers, Daewoong operates in both domestic and international markets, particularly in the spheres of intractable and rare disease treatments.
This esteemed company boasts a diverse portfolio that includes novel drugs, biologics, new products, research, and development driven by open collaboration and advanced manufacturing capabilities. Daewoong has marked significant milestones in drug development, successfully launching innovative medications for conditions like gastroesophageal reflux disease (GERD) and Type 2 diabetes, with cutting-edge ingredients such as Fexuprazan and Enavogliflozin.
The company is also at the forefront of developing a First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS inhibitor. Noteworthy is that Bersiporocin has received designations from the U.S. FDA as an orphan drug and a product fast-tracked for development.
Frequently Asked Questions
What is the main purpose of the Salipro Biotech and Daewoong Pharmaceutical collaboration?
The main purpose of the collaboration is to leverage Salipro's expertise and platform technology to facilitate the development of novel small molecule drugs targeting challenging membrane proteins.
Who are the key executives involved in this partnership?
The key executives involved are Jens Frauenfeld, CEO of Salipro Biotech, and Seongsoo Park, CEO of Daewoong Pharmaceutical.
Where is Salipro Biotech headquartered?
Salipro Biotech is headquartered in Stockholm, Sweden.
What types of products does Daewoong Pharmaceutical develop?
Daewoong Pharmaceutical develops a variety of products, including novel drugs, biologics, and treatments for rare diseases.
What is unique about Salipro’s technology?
Salipro's technology stabilizes membrane proteins to enable their use in drug discovery, allowing for improved therapeutic development.
